McBride v. Merrell Dow and Pharmaceuticals, Inc.

Decision Date13 June 1985
Docket NumberCiv. A. No. 81-2639.
Citation613 F. Supp. 1349
PartiesWilliam G. McBRIDE, M.D., Plaintiff, v. MERRELL DOW AND PHARMACEUTICALS, INC., et al., Defendants.
CourtU.S. District Court — District of Columbia

Allen T. Eaton, W. David Allen, Allen T. Eaton & Associates, Washington, D.C., for plaintiff.

Robert X. Perry, Jr., Wilkes, Artis, Hedrick & Lane, H. Thomas Howell, Sidney G. Leech, Semmes, Bowen & Semmes, Washington, D.C., for defendants.

MEMORANDUM OPINION

BARRINGTON D. PARKER, District Judge:

This defamation action comes before the Court on the parties' cross-motions for summary judgment following remand from the Court of Appeals. The action arises from the publication of an article entitled "How Safe Is Bendectin?" in Science magazine on October 31, 1980. The Court of Appeals affirmed in part and reversed in part this Court's initial decision dismissing the plaintiff's complaint for failure to state a cause of action. McBride v. Merrell Dow and Pharmaceuticals, Inc., 717 F.2d 1460, 1467 (D.C.Cir.1983). The text of the article is attached to this opinion as Appendix A. This Court had dismissed the complaint after holding that "nothing in the article is found capable of bearing a defamatory meaning." 540 F.Supp. 1252, 1255 (D.D.C. 1982). With respect to all but one of the allegedly defamatory statements, the Court of Appeals agreed. 717 F.2d at 1464-65. The Court of Appeals noted that it was "troubled" by improbability of this single remaining claim, id. at 1461, 1466 and suggested that this Court

proceed upon remand in a manner that will minimize, so far as practicable, the burden a possibly meritless claim is capable of imposing upon free and vigorous journalism.

Id. at 1462. With these remarks in mind, the Court will briefly discuss the background of this litigation,1 the Court of Appeals' holding in light of the questions which must be decided on remand, and the reasons supporting the conclusion that the plaintiff cannot as a matter of law prevail in this action.

A. FACTUAL BACKGROUND

The plaintiff in this action is Dr. William G. McBride, a world-renowned expert in the field of teratology, the study of birth defects. Complaint at ¶¶ 1, 13. Dr. McBride, an Australian, first acquired his reputation through research directed at the relationship between the drug thalidomide and certain birth defects. The Science article was published after Dr. McBride's trip to the United States to testify before the Food and Drug Administration ("FDA") about the safety of another drug, Bendectin, which has also been associated with certain birth defects. The hearing took place several months after Dr. McBride testified as an expert witness on behalf of the plaintiffs in an Orlando, Florida lawsuit which sought recovery for birth defects allegedly caused by the use of Bendectin. Mekdeci v. Merrell National Laboratories, No. 77-255 (M.D.Fla.).2

In connection with a general discussion about the safety of Bendectin, the Science article made several assertions about the various experts who testified both for the plaintiffs at the Mekdeci trial and before the FDA panel. With respect to Dr. McBride, the article stated, among other things, that he

was paid $5,000 a day to testify in Orlando. In contrast, Richardson-Merrell, pays witnesses $250 to $500 a day, and the most it has ever paid is $1,000 a day.

Although several statements about Dr. McBride were challenged as defamatory, the witness fee statement is the only assertion which survives the Court of Appeals' ruling.

The defendants in this litigation are Gina Bari Kolata, the author of the article, the American Association for the Advancement of Science ("the Association"), the publisher of Science magazine, three Merrell Dow corporate entities, the manufacturer of Bendectin, Frederic Lamb, Merrell Dow's general counsel, and Robert Irvine, a public relations officer at Merrell Dow.3 Ms. Kolata and the Association are charged with responsibility for the witness fee statement and its dissemination. The complaint against the individual and corporate Merrell Dow defendants rests on two grounds: statements made during alleged communications with Ms. Kolata and subsequent dissemination of the article. Specifically, the complaint alleges that defendant Irvine, at the behest of his employer and Lamb, "spread lies and deceit" to Ms. Kolata, Complaint ¶ 8, and that Merrell Dow "planted false and scurrilous statements" in the article. Id., ¶ 13. After remand, the only possibly actionable statement which can be attributed to Merrell Dow is their alleged statement that they generally paid their experts $250-$500 a day to testify, and had never paid an expert more than $1,000 per day. Id., ¶ 13(b).

In contrast, the complaint does not assign responsibility for the statement about Dr. McBride's remuneration to Merrell Dow. Although the source of this statement is not alleged in the complaint, id., it is apparently based on the remarks of Melvin Belli, an attorney of record in the Mekdeci case. The Court of Appeals referred to public statements made by Belli that "it cost me $5,000 a day to bring Dr. McBride to the Mekdeci case," and "we've got a guy, McBride, here from Australia, $5,000 a day." 717 F.2d at 1464 n. 6 (citations omitted).

The complaint further alleges that Merrell Dow subsequently disseminated the article "as part of its scheme to silence plaintiff, indoctrinate the scientific community and avoid or stall access to the courts for maimed babies." Complaint ¶ 12. The activities of all the defendants were allegedly done "with actual malice." Id., ¶ 22.

B. THE COURT OF APPEALS OPINION

As already noted, the Court of Appeals held that only the witness fee statement could possibly state a claim upon which relief can be granted. It opined that:

it is not possible for us to conclude, however, that the published statement that McBride was paid $5,000 a day to testify in the Florida trial, particularly when directly compared with the amounts Merrell Dow paid its expert witnesses, is incapable of bearing a defamatory meaning.

717 F.2d at 1465. The Court cautioned that in the event the plaintiff is found to be a public figure, he must prove actual malice in order to prevail.4 The Court gave its opinion that

though the district court did not rule upon the point and we do not foreclose any decision that court may make after briefing and argument, we think it highly likely, in the context in which this case arises, at least, that Dr. McBride is a limited public figure.

Id. at 1466.

Finally, the Court urged that if the plaintiff was determined to be a public figure, discovery after remand should, at least initially, be confined to issues which might support summary disposition of the case. This is because "suits — particularly those bordering on the frivolous — should be controlled so as to minimize their adverse impact upon press freedom." This Court construes these remarks to mean that if Dr. McBride is a public figure, the question of actual malice might be decided on summary judgment.

This Court thus directed that discovery be limited initially to two issues which, taken together, might support summary judgment. First, the Court directed the parties to explore Dr. McBride's status as a public figure. Second, the Court permitted discovery on the question of the fee Dr. McBride earned in the Florida trial. It was anticipated that both of these inquiries would shed some light on the issue of whether Dr. McBride could ultimately prevail at trial on the question of actual malice.

In limiting the scope of discovery on remand, the Court relied in part on the Court of Appeals' statement that "should the district court rule that McBride is a public figure, the sense in which the fee statement is true would make it extremely difficult, if not impossible, to prove actual malice." (Memorandum Order denying rehearing en banc, filed Feb. 22, 1984). Normally, the question of the truth of a statement should be decided by the jury, and the question of actual malice should only be resolved after conducting an inquiry into the state of mind of the author. Here, however, the resolution of the first question, coupled with the special circumstances of this case, makes discovery specifically directed to actual malice burdensome and unnecessary. Based on the proceedings conducted after remand, the Court concludes that summary judgment for the defendants is warranted.

C.

DETERMINATIONS AFTER REMAND

Public Figure Status

Defamation law recognizes two types of public figures: general and limited public figures. A general or all-purpose public figure is a person who enjoys "general fame or notoriety in the community." Gertz v. Robert Welch, Inc., 418 U.S. 323, 351-52, 94 S.Ct. 2997, 3012-13, 41 L.Ed.2d 789 (1974). In contrast, a limited-purpose public figure is "an individual who voluntarily injects himself or is drawn into a particular public controversy and therefore becomes a public figure for a limited range of issues." Id. at 351, 94 S.Ct. at 3013. After considering these standards, the Court rejects the defendants' suggestion that Dr. McBride may have acquired the status of a general public figure, but agrees that he is a limited public figure for purposes of this litigation.

The decision in Waldbaum v. Fairchild Publications, Inc., 627 F.2d 1287 (D.C.Cir.), cert. denied, 449 U.S. 898, 101 S.Ct. 266, 66 L.Ed.2d 128 (1980) sets out the appropriate framework for the limited public figure analysis. It directs the Court to determine whether a public controversy exists, examine the nature of the plaintiff's role in the controversy, and consider whether the alleged defamation was relevant to the controversy. Id. at 1296-98. Prototypical public figures are those individuals who have "thrust themselves to the forefront of particular public controversies in order to influence the resolution of the issues involved ... they invite attention and comment." Gertz, 418 U.S. at 345, 94 S.Ct....

To continue reading

Request your trial
3 cases
  • Spence v. Flynt
    • United States
    • U.S. District Court — District of Wyoming
    • November 3, 1986
    ...or continuing to distribute the publication. This Court agrees with the standard set forth in McBride v. Merrell Dow and Pharmaceuticals, Inc., 613 F.Supp. 1349, 1356-1357 (D.C.D.C.1985): Liability for dissemination of defamatory material is not open-ended. The Courts have required a showin......
  • McBride v. Merrell Dow and Pharmaceuticals, Inc.
    • United States
    • U.S. Court of Appeals — District of Columbia Circuit
    • September 12, 1986
    ...was false. On cross-motions of the parties, the district court entered summary judgment against McBride. McBride v. Merrell Dow and Pharmaceuticals, Inc., 613 F.Supp. 1349 (D.D.C.1985). The district court held that McBride was a "public figure" for purposes of the first amendment and could ......
  • Dworkin v. LFP, INC., C85-0471-B.
    • United States
    • U.S. District Court — District of Wyoming
    • November 18, 1986
    ...Distrib. Co., Inc., 745 F.2d 123 (2d Cir.1984); Dworkin v. Hustler, 622 F.Supp. 781 (D.C.Wyo. 1985); McBride v. Merrell Dow and Pharmaceuticals, Inc., 613 F.Supp. 1349 (D.C.D.C.1985); Lewis v. Time, Inc., 83 F.R.D. 455 (E.D.Cal. ...

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT